SCHEMBL4767671

SCHEMBL4767671

COC(=O)c1ccc(N(Cc2cccc(Cl)c2Cl)S(C)(=O)=O)c(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.51
LMNA P02545 3/20 0.51
POLB P06746 4/20 0.48
MCOLN3 Q8TDD5 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.43
CYP1A2 P05177 1/20 0.43
TSHR P16473 1/20 0.43
CYP2C19 P33261 1/20 0.43
GAA P10253 3/20 0.42
ALDH1A1 P00352 4/20 0.41
KMT2A Q03164 3/20 0.41
HPGD P15428 1/20 0.41
ACLY P53396 1/20 0.39
MEN1 O00255 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767773 0.91 LMNA (0.49) MAPTLMNAPOLBMCOLN3SMN1; SMN2
SCHEMBL4777409 0.86 ALDH1A1 (0.51) MAPTLMNAPOLBMCOLN3SMN1; SMN2
SCHEMBL4771011 0.85 LMNA (0.49) MAPTLMNAPOLBMCOLN3SMN1; SMN2
SCHEMBL4777540 0.83 POLB (0.54) MAPTLMNAPOLBMCOLN3SMN1; SMN2
SCHEMBL18460409 0.80 POLB (0.54) MAPTPOLBMCOLN3SMN1; SMN2CYP1A2
SCHEMBL4771125 0.78 MAPT (0.55) MAPTLMNAPOLBSMN1; SMN2CYP1A2
SCHEMBL4777497 0.78 MAPT (0.49) MAPTLMNAPOLBSMN1; SMN2CYP1A2
SCHEMBL4768135 0.78 MAPT (0.49) MAPTLMNAPOLBSMN1; SMN2CYP1A2
SCHEMBL4777650 0.77 GAA (0.60) MAPTLMNAPOLBSMN1; SMN2GAA
SCHEMBL4776409 0.77 MAPT (0.48) MAPTLMNAPOLBSMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 MAPT 294/4885LMNA 1022/4885POLB 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.